Results 81 to 90 of about 113,904,810 (178)
Cancer Reports, Volume 9, Issue 2, February 2026.ABSTRACT Background Nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil (5‐FU)/levo‐leucovorin (Levo‐LV) therapy is recommended as the standard of care for unresectable locally advanced (UR‐LA) and metastatic pancreatic cancer after failure of gemcitabine‐containing regimens.
Akane Wakabayashi +7 more
wiley +1 more source
Journal of Pharmacological Sciences, 2008 The pharmacological properties of T-2328 were evaluated as an antagonist of the tachykinin neurokinin 1 (NK1) receptor. T-2328 inhibited the specific binding of [3H][Sar9,Met(O2)11]substance P to tachykinin NK1receptors in human lymphoblastic IM9 cells ...
Yumi Watanabe +7 more
doaj +1 more source
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
Indian Journal of Medical and Paediatric Oncology, 2019 Chemotherapy-induced nausea and vomiting (CINV) is a significant contributor to the treatment morbidity experienced by patients with cancer. With effective prophylactic anti-emetics given prior to administration of moderately or highly emetogenic ...
Venkatraman Radhakrishnan
doaj +1 more source
Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting
, 2012 For patients receiving cancer chemotherapy, the ongoing development of antiemetic treatment is of significant importance. Patients consider nausea and vomiting among the most distressing symptoms of chemotherapy, and as new antiemetics have been very ...
Herrstedt, Jørn +1 more
core +1 more source
, 2021 유방암은 여성호르몬 수용체 양성, HER2 양성, 삼중음성유방암 3가지로 분류하며, 그 중 HER2 양성 유방암은 전체 유방암 중 25% 정도를 차지하고 있다. HER2 양성 유방암은 일반적인 유방암에 비해 공격적인 진행 양상을 보이나, HER2를 타깃으로 한 표적치료제가 가장 먼저 개발 되어 치료에 도입되면서 이전에 비해 환자들의 예후가 매우 향상되었다.
이경민
core +1 more source
Indian Journal of Anaesthesia, 2019 Background and Aims: Aprepitant, a Neurokinin-1 receptor antagonist, has been evaluated in abdominal and neurosurgeries, but its effect is less clear in breast and thyroid surgeries, which are also known to be high risk for post-operative nausea and ...
Salome Jeyabalan +3 more
doaj +1 more source
Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting
, 2004 Aprepitant is an oral neurokinin-1 receptor antagonist which acts centrally to block chemotherapy-induced emesis. Its main pathway of elimination is by the cytochrome p450 isozyme CYP3A4, which is the basis for drug interactions with dexamethasone and ...
Olver, I.
core +1 more source
Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary to Sézary Syndrome [PDF]
, 2012 Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may have an important role in ...
Fernandes, I. +4 more
core +1 more source
Pilot Study of Aprepitant for Prevention of Post-ERCP Pancreatitis in High Risk Patients: A Phase II Randomized, Double-Blind Placebo Controlled Trial [PDF]
, 2012 Objectives Animal studies have demonstrated a role for substance P binding to neurokinin-1 receptor in the pathogenesis of acute pancreatitis. Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post-ERCP ...
Obando, Jorge +5 more
core +1 more source